



WORLDWIDE NETWORK FOR BLOOD AND MARROW TRANSPLANTATION

www.wbmt.org

EDUCATION AND DISSEMINATION COMMITTEE

WBMT Webinar

CAR-T or Autologous/Allogeneic HCT for Relapsed and Refractory DLBCL: Current Paradigms and Remaining Controversies

26 October 2026 | Monday @ 1:00 pm – 2:30 pm CET | Zoom Webinar

The Education & Dissemination Committee of the WBMT is organizing a webinar to discuss evolving treatment strategies for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), highlighting the role of CAR T-cells and HCT, including their role in the settings of broad and limited access to cellular therapies. Expert speakers will discuss current paradigms, share clinical insights and address ongoing controversies shaping patient care. You are cordially invited.

WEBINAR PROGRAM:**Chairpersons:**

Christian Chabannon, *Aix Marseille Université (AMU) School of Medicine, France*
Mohamed Khafan-Dabaja, *Mayo Clinic Comprehensive Cancer Center, USA*

1:00 – 1:05 PM	Welcome Note	Dietger Niederwieser and Adriana Seber
1:05 – 1:15 PM	Case Presentation	Mohamed Kharfan-Dabaja <i>Mayo Clinic Comprehensive Cancer Center, USA</i>
1:15 – 1:40 PM	CAR T-cell Therapy for Relapsed/Refractory DLBCL	Marco Ruella <i>University of Pennsylvania, USA</i>
1:40 – 2:05 PM	Autologous/Allogeneic HCT for Relapsed/Refractory DLBCL	Anna Sureda <i>Institut Català d'Oncologia-Hospitalet, Institut d'Investigació Biomèdica de Bellvitge, Spain</i>
2:05 – 2:25 PM	Pannel discussion: What happens to the patient?	Moderators: Christian Chabannon <i>Aix Marseille Université (AMU) School of Medicine, France</i> Mohamed Khafan-Dabaja <i>Mayo Clinic Comprehensive Cancer Center, USA</i>
2:25 – 2:30 PM	Closing Remarks	Dietger Niederwieser and Adriana Seber

REGISTRATION IS FREE
[Click here to register](#)